Am. J. Respir. Cell Mol. Biol., Volume 24, Number 2, February, 2001 187-194

Polarization of PPD-Specific T-Cell Response of Patients with Tuberculosis from Th0 to Th1 Profile after Successful Antimycobacterial Therapy or In Vitro Conditioning with Interferon- or Interleukin-12

Arnaud Marchant, Amedeo Amedei, Annalisa Azzurri, Johan Vekemans, Marisa Benagiano, Carlo Tamburini, Christian Lienhardt, Tumani Corrah, Keith P. W. J. McAdam, Sergio Romagnani, Mario M. D'Elios, and Gianfranco Del Prete

Medical Research Council Laboratories, Fajara, The Gambia; and Department of Internal Medicine, University of Florence, Florence, Italy

The T helper (Th) 1/Th2 balance in the T-lymphocyte response to purified protein derivative (PPD) was evaluated at the clonal level in six Italian and five Gambian patients with pulmonary tuberculosis (TB) before and after antimycobacterial therapy, as well as in five Gambian and four Italian healthy immune control subjects. In untreated patients, most PPD-specific clones derived from either peripheral blood or pleural effusions showed a Th0 cytokine profile (production of both interferon [IFN]- and interleukin [IL]-4/IL-5). After 6 mo of therapy and clinical healing, most PPD-specific clones showed a polarized Th1 profile (production of IFN- but not IL-4/IL-5) in both Italian and Gambian patients. The Th1 polarization was less marked in Gambian than in Italian patients and failed to occur in another group of four Italian patients who experienced treatment failure. The cytokine profile observed after successful therapy in patients with TB was similar to that found in healthy control subjects. T-cell clones of undefined specificity generated from PPD-stimulated cultures showed a similar Th0/Th2 bias in Gambian individuals and Italian patients with treatment failure. The Th0/Th2-biased responses in Gambian patients before therapy could be modulated in vitro by IFN- or IL-12, which induced a Th1 polarization of both PPD-specific and bystander T cells. Our data show that active TB associates with a predominant Th0 response to mycobacterial antigens that could play a role in the pathogenesis of the disease. Adjunctive immunotherapy using Th1-polarizing cytokines could increase host defense against mycobacteria and accelerate healing.

This article has been cited by other articles:

				T. M. Doherty and P. Andersen Vaccines for Tuberculosis: Novel Concepts and Recent Progress Clin. Microbiol. Rev., October 1, 2005; 18(4): 687 - 702. [Abstract] [Full Text] [PDF]

				K. Dheda, J.-S. Chang, R. A. M. Breen, L. U. Kim, J. A. Haddock, J. F. Huggett, M. A. Johnson, G. A. W. Rook, and A. Zumla In Vivo and In Vitro Studies of a Novel Cytokine, Interleukin 4{delta}2, in Pulmonary Tuberculosis Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 501 - 508. [Abstract] [Full Text] [PDF]

				B. D. Westenbrink, Y. Stienstra, M. G. Huitema, W. A. Thompson, E. O. Klutse, E. O. Ampadu, H. M. Boezen, P. C. Limburg, and T. S. van der Werf Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana Clin. Vaccine Immunol., January 1, 2005; 12(1): 125 - 129. [Abstract] [Full Text] [PDF]

				A. Demissie, M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, and T. M. Doherty Healthy Individuals That Control a Latent Infection with Mycobacterium tuberculosis Express High Levels of Th1 Cytokines and the IL-4 Antagonist IL-4{delta}2 J. Immunol., June 1, 2004; 172(11): 6938 - 6943. [Abstract] [Full Text] [PDF]

				J. Vekemans, M. O. C. Ota, J. Sillah, K. Fielding, M. R. Alderson, Y. A. W. Skeiky, W. Dalemans, K. P. W. J. McAdam, C. Lienhardt, and A. Marchant Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design Infect. Immun., January 1, 2004; 72(1): 381 - 388. [Abstract] [Full Text] [PDF]

				G. Fenhalls, G. R. Squires, L. Stevens-Muller, J. Bezuidenhout, G. Amphlett, K. Duncan, and P. T. Lukey Associations between Toll-Like Receptors and Interleukin-4 in the Lungs of Patients with Tuberculosis Am. J. Respir. Cell Mol. Biol., July 1, 2003; 29(1): 28 - 38. [Abstract] [Full Text] [PDF]